Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang, Ph.D. will present company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT.
The presentation will be available via a live webcast on Legend Biotech's Investor Relations website, and a replay will be posted approximately 48 hours after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – LEGN
In the Dec 17 session, LEGN declined 1.06%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | R&D facility opening | Positive | -0.5% | Opened new 31,000-square-foot Philadelphia cell therapy R&D facility. |
| Nov 12 | Quarterly earnings update | Positive | -2.7% | Reported strong CARVYKTI sales and about $1.0B cash/time deposits. |
| Nov 03 | ASH presentations news | Positive | -0.8% | Announced 10 ASH presentations including CARVYKTI and Lucar-G39D data. |
| Oct 29 | Earnings call announcement | Neutral | -1.4% | Scheduled investor call to review third quarter 2025 results. |
| Aug 26 | Conference participation | Neutral | +1.4% | Planned CEO fireside chat at Morgan Stanley Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and clinical updates have often coincided with modest negative next-day price reactions, suggesting a pattern of selling into news.
Over the last few months, Legend Biotech has reported several operational and clinical milestones. On November 13, 2025, it opened a new 31,000-square-foot R&D facility in Philadelphia, while Q3 2025 results on November 12 highlighted strong CARVYKTI sales and about $1.0 billion in cash and time deposits, yet shares slipped after both updates. Earlier in November, the company announced 10 ASH 2025 presentations. Conference participation in August at the Morgan Stanley Global Healthcare Conference was one of the few events followed by a positive price move. Today’s J.P. Morgan conference appearance fits into this pattern of active investor and scientific engagement.
Key Terms
cell therapy medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT.
The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.
ABOUT LEGEND BIOTECH
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
media@legendbiotech.com
